Cargando…

Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis

Objective: A window period of approximately 3–6 months is usually adopted in studies that evaluate hepatic encephalopathy (HE) risk in proton pump inhibitor (PPI) users. However, HE risk after short-term PPI exposure remains unclear. We explored the effect of short-term PPI exposure using a case-cro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuan, Yi-Chun, Huang, Kuang-Wei, Lin, Cheng-Li, Luo, Jiing-Chyuan, Kao, Chia-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723586/ https://www.ncbi.nlm.nih.gov/pubmed/31349746 http://dx.doi.org/10.3390/jcm8081108

Ejemplares similares

Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis
por: De Roza, Marianne Anastasia, et al.
Publicado: (2019)

Electroencephalography Signatures for Hepatic Encephalopathy in Cirrhosis Patients Treated with Proton Pump Inhibitors: An Exploratory Pilot Study
por: Zhang, Pan, et al.
Publicado: (2022)

Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients
por: Fasullo, Matthew, et al.
Publicado: (2019)

The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan
por: Sakamaki, Akira, et al.
Publicado: (2021)

Effects of Aspirin or Clopidogrel on Colorectal Cancer Chemoprevention in Patients with Type 2 Diabetes Mellitus
por: Kuan, Yi-Chun, et al.
Publicado: (2019)

Association between proton pump inhibitors and hepatic encephalopathy: A meta-analysis
por: Bian, Jin, et al.
Publicado: (2017)

Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients
por: Romano, John, et al.
Publicado: (2018)

Primary prophylaxis of hepatic encephalopathy in decompensated cirrhosis: Low dose vs. full dose rifaximin
por: Sarwar, Shahid, et al.
Publicado: (2019)

Safe use of proton pump inhibitors in patients with cirrhosis
por: Weersink, Rianne A., et al.
Publicado: (2018)

Treatment of Hepatitis B in Decompensated Liver Cirrhosis
por: Guan, Richard, et al.
Publicado: (2011)

Randomized intervention and outpatient follow-up lowers 30-d readmissions for patients with hepatic encephalopathy, decompensated cirrhosis
por: Pusateri, Antoinette, et al.
Publicado: (2023)

Low Prealbumin Levels Were Associated with Increased Frequency of Hepatic Encephalopathy in Hepatitis B Virus (HBV)-Related Decompensated Cirrhosis
por: Li, Jiani, et al.
Publicado: (2023)

Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis
por: Tantai, Xin-Xing, et al.
Publicado: (2019)

Proton pump inhibitor use increases hepatic encephalopathy risk: A systematic review and meta-analysis
por: Ma, Yun-Jie, et al.
Publicado: (2019)

Association of Proton Pump Inhibitor Therapy with Hepatic Encephalopathy in Hepatitis B Virus-related Acute-on-Chronic Liver Failure
por: Lin, Zhao-Ni, et al.
Publicado: (2014)

Proton Pump Inhibitor Therapy Does Not Affect Prognosis of Cirrhosis Patients With Acute Decompensation and Acute-on-Chronic Liver Failure: A Single-Center Prospective Study
por: Sun, Shanshan, et al.
Publicado: (2021)

Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis
por: Kotani, Kohei, et al.
Publicado: (2023)

SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation
por: Kaplan, David E., et al.
Publicado: (2021)

Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis
por: Horvath, Angela, et al.
Publicado: (2019)

Nutritional Deficiencies and Clinical Practices in Decompensated Cirrhotics With Hepatic Encephalopathy
por: Panchani, Nishah N, et al.
Publicado: (2022)

Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology
por: Butterworth, Roger F.
Publicado: (2019)

Hepatic encephalopathy due to cardiac cirrhosis
por: Ono, Ryohei, et al.
Publicado: (2023)

Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges
por: Zhao, Hong, et al.
Publicado: (2020)

Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy
por: Lee, Seohyuk, et al.
Publicado: (2023)

Association Between Cholangiocarcinoma and Proton Pump Inhibitors Use: A Nested Case-Control Study
por: Peng, Yen-Chun, et al.
Publicado: (2018)

Improving Survival in Decompensated Cirrhosis
por: Mukerji, Amar Nath, et al.
Publicado: (2012)

Management options in decompensated cirrhosis
por: Shah, Neeral L, et al.
Publicado: (2015)

COVID-19 in decompensated cirrhosis
por: Rela, Mohamed, et al.
Publicado: (2020)

Decompensation of Cirrhosis: An Unusual Cause
por: Rudra, Omkar S, et al.
Publicado: (2022)

Proton pump inhibitor use is associated with a variety of infections in patients with liver cirrhosis
por: Labenz, Christian, et al.
Publicado: (2020)

Hepatic Venous Pressure Gradient Predicts Long-Term Mortality in Patients with Decompensated Cirrhosis
por: Kim, Tae Yeob, et al.
Publicado: (2016)

Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis
por: Ju, Young-Cheol, et al.
Publicado: (2018)

Hepatic Hydrothorax—An Independent Decompensating Event Associated with Long-Term Mortality in Patients with Cirrhosis
por: Matei, Daniela, et al.
Publicado: (2021)

Long-Term Usage of Proton Pump Inhibitors Associated with Prognosis in Patients with Colorectal Cancer
por: Wu, Chin-Chia, et al.
Publicado: (2023)

Hepatic Myelopathy in a Patient with Decompensated Alcoholic Cirrhosis and Portal Colopathy
por: Premkumar, Madhumita, et al.
Publicado: (2012)

Serum Sphingolipid Variations Associate with Hepatic Decompensation and Survival in Patients with Cirrhosis
por: Grammatikos, Georgios, et al.
Publicado: (2015)

Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis
por: Liu, Hui, et al.
Publicado: (2016)

Invasive pulmonary mucormycosis and aspergillosis in a patient with decompensated hepatic cirrhosis
por: Persichino, Jon G., et al.
Publicado: (2018)

Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis
por: Lee, Soon Kyu, et al.
Publicado: (2017)

Postoperative Risk of Hepatic Decompensation after Orthopedic Surgery in Patients with Cirrhosis
por: Nyberg, Eric M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0lh1u6gami6f7j1jgq8jmsd2no